Sixteen healthy lean volunteers (eight men and eight women). Fasted subjects received subcutaneous injections of ghrelin (3.6 nmol/kg) or saline. After 30 min, a buffet breakfast was served.

Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME ...

The subcutaneous administration (under the skin) of bortezomib, a standard treatment in patients with multiple myeloma (cancer of the bone marrow), is as effective as standard intravenous delivery ...

Subcutaneous administration led to 8.1% of patients overall having local injection site reactions (15.3% in lecanemab-naive patients). Most were mild and moderate in severity consisting of redness ...

However, in December 2024, the Food and Drug Administration (FDA) approved a new version of nivolumab (Opdivo Qvantig) for use as a subcutaneous injection. This means the drug can be injected ...

Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...

2. U.S. Food and Drug Administration accepts Bristol Myers Squibb’s application for subcutaneous nivolumab (nivolumab and hyaluronidase). News Release. Bristol Myers Squibb. May 8, 2024.

MILAN — Subcutaneous administration of anti-CD20 monoclonal antibody therapy offers ongoing clinical efficacy in the management of patients with relapsing and primary progressive multiple ...

The subcutaneous formulation also significantly reduced drug administration time (7.4 minutes vs. 61.6 minutes; P < .0001) and treatment experience time (96 minutes vs. 177.8 minutes; P < .0001).

Subcutaneous injections were administered at a dose of 1.3 mg/m 2 reconstituted in saline solution (1.4 mL) for a final concentration of 2.5 mg/mL. For the first 12 weeks, patients received ...

The Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), a subcutaneous injection, for all previously approved indications of the intravenous ...